Dutch AI Startup Raises €2.3 Million to Prevent Surgery Infections
Netherlands, Saturday, 24 January 2026.
Healthplus.ai secured €2.3 million to deploy PERISCOPE®, an AI system that predicts patient-specific infection risks after surgery and provides targeted action plans for healthcare teams.
Healthtech Innovation Targeting Critical Healthcare Challenge
This development represents a significant advancement in the healthtech sector, specifically targeting one of healthcare’s most pressing challenges: postoperative complications [1]. The Dutch MedTech scale-up Healthplus.ai has positioned itself at the intersection of artificial intelligence and surgical care, focusing on infection prevention rather than treatment [1]. The company’s PERISCOPE® platform represents a proactive approach to healthcare management, utilizing machine learning algorithms to analyze patient data and predict infection risks before they materialize [1]. Founded and led by CEO dr. Bart Geerts, the company operates from Amsterdam, placing it within one of Europe’s most dynamic AI and life sciences ecosystems [1][3].
How PERISCOPE® Technology Works
The PERISCOPE® system transforms existing electronic health record data into precise, actionable risk predictions across the full surgical pathway [4]. The platform integrates seamlessly with leading hospital systems including Epic, Oracle Cerner, and ChipSoft, which serve the Dutch and broader European healthcare markets [1]. The technology employs automatic calibration to ensure predictions remain accurate across different types of hospitals while maintaining compliance with all relevant regulations [1]. The system continuously learns from real-world outcomes, applying robust local recalibration for high predictive accuracy [4]. Rather than simply flagging high-risk patients, PERISCOPE® provides targeted action plans for healthcare teams, enabling proactive risk management in operating rooms [1].
Strategic Funding and Market Impact
The €2.3 million late-seed funding round, announced in November 2025, was led by Elevating Capital and LUMO Labs, with participation from Pathena Venture Capital, Leistone (Renza Family), and ROM InWest [1][4]. This financing reflects strong investor confidence in the company’s clinical impact, scalability, and regulatory-first approach [4]. The technology addresses a substantial economic burden, with the potential to save hospitals up to €4 million per year by reducing postoperative complications, which represent both a significant cost center and source of workforce pressure [1]. The system is already demonstrating measurable impact in clinical settings, including reduced complications, shorter recovery times, and meaningful hospital cost savings [4].
Expansion Plans and Regional Significance
Healthplus.ai plans to use the new capital to accelerate its rollout across Europe and initiate expansion into the United States, with initial U.S. pilots already underway [4]. The company is currently expanding its footprint across the Netherlands, Belgium, Denmark, and the UK, while preparing for broader expansion into the Nordics and North America [4]. The company is on track for break-even in Europe in 2026 while advancing toward FDA clearance with leading U.S. health system partners [4]. As noted by Sara Schaafsma, Investment Manager at ROM InWest, the technology enables doctors and nurses to create better treatment plans, intervene faster with high-risk patients, and safely discharge low-risk patients earlier, contributing to a more efficient healthcare system [1]. CEO Bart Geerts is scheduled to present the company at LSI USA ‘26 from March 16-20, 2026, in Dana Point, California [4].